MedAdvisor Limited (AU:AHE)
ASX:AHE
Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.14
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$12.75M
Enterprise ValueAU$16.33M
Total Cash (Recent Filing)AU$10.30M
Total Debt (Recent Filing)AU$17.40M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding637,676,800
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$110.67M
Bulls Say, Bears Say
Bulls Say
Pharmacy-focused Platform And Consumer AppMedAdvisor operates a pharmacy-focused software platform plus a consumer medication app that supports prescription/refill workflows and adherence. These capabilities create recurring, sticky interactions with pharmacies and patients, producing durable demand and network effects that underpin long-term revenue resilience.
Improving Free Cash FlowAn 18.49% free cash flow growth rate indicates improving cash generation versus prior periods. For a loss-making tech-health company, rising FCF suggests progress in converting operations to cash, reducing reliance on external financing and providing a firmer base to fund investment or stabilize operations over the coming months.
Positive Return On EquityThe reported positive return on equity implies management can generate returns from the equity base despite overall weakness. While equity is currently negative, a positive ROE signals operational efficiency in revenue-to-equity conversion, a structural capability that can accelerate recovery if scale or margins improve.
Bears Say
Sharp Revenue DeclineA near 40% decline in revenue represents a material contraction in core commercial performance. Sustained top-line shrinkage erodes scale benefits, limits ability to absorb fixed costs, hinders reinvestment in product and sales, and makes medium-term recovery and margin restoration more difficult without structural revenue fixes.
Deep And Persistent UnprofitabilityExtremely negative net margins and negative EBIT/EBITDA point to a cost base well outstripping revenues. This structural unprofitability drives ongoing cash burn, constrains reinvestment, and increases the need for external capital unless the company can materially cut costs or restore revenue over the next several quarters.
Negative Equity And Solvency RiskNegative shareholders' equity and an extreme debt-to-equity ratio indicate capital impairment and potential solvency issues. This structural balance-sheet weakness reduces financial flexibility, raises refinancing and covenant risks, and may force dilutive or costly funding choices that impair long-term strategic options.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.02 and its highest was AU$0.14 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$12.75M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 109 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.011.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,676,800 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$64.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
-137.16%
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
Options Prices
Currently, No data available
---